

Research Article: Theory/New Concepts / Novel Tools and Methods

A Multilevel Computational Characterization of Endophenotypes in Addiction

Vincenzo G. Fiore¹, Dimitri Ognibene^{2,3}, Bryon Adinoff^{4,5} and Xiaosi Gu^{1,6}

¹School of Behavioral and Brain Sciences, University of Texas at Dallas, 800 W. Campbell Road, Richardson TX 75080-3021, USA

²Department of Computer Science and Electronic Engineering, University of Essex, Colchester CO4 3SQ, UK

³Department of Information and Communication Technologies, Universitat Pompeu Fabra, Barcelona 08018, ES

⁴University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas TX 75390, USA

⁵VA North Texas Health Care System, 4500 S. Lancaster Rd, Dallas TX 75216, USA

⁶Department of Psychiatry, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York NY 10029-5674, USA

DOI: 10.1523/ENEURO.0151-18.2018

Received: 11 April 2018

Revised: 6 June 2018

Accepted: 12 June 2018

Published: 3 July 2018

Author Contributions: VGF and DO: Designed research, Performed research, Analyzed data, Wrote the paper. BA and XG Analyzed data, Wrote the paper.

Conflict of Interest: Authors report no conflict of interest.

This work is supported by the Dallas Foundation and a startup grant from UT Dallas.

Correspondence should be addressed to either Vincenzo G. Fiore, School of Behavioral and Brain Sciences, UT Dallas, 800 W. Campbell Road, Richardson, TX 75080-3021, USA. E-mail: vincenzo.g.fiore@gmail.com [MAIL] or Xiaosi Gu, School of Behavioral and Brain Sciences, UT Dallas, 800 W. Campbell Road, Richardson, TX 75080-3021, USA. E-mail: xiaosi.gu@utdallas.edu

Cite as: eNeuro 2018; 10.1523/ENEURO.0151-18.2018

Alerts: Sign up at eneuro.org/alerts to receive customized email alerts when the fully formatted version of this article is published.

Accepted manuscripts are peer-reviewed but have not been through the copyediting, formatting, or proofreading process.

Copyright © 2018 Fiore et al.
This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

1 **Manuscript Title:** A Multilevel Computational Characterization of Endophenotypes in

2 Addiction

3

4 **Abbreviated Title:** Computational Endophenotypes in Addiction

5

6 **List all Author Names and Affiliations in order as they would appear in the published**
7 **article**

8 Vincenzo G. Fiore¹, Dimitri Ognibene^{2,3}, Bryon Adinoff^{4,5}, Xiaosi Gu^{1,6}

9 1 - School of Behavioral and Brain Sciences, University of Texas at Dallas, 800 W. Campbell
10 Road, Richardson, TX 75080-3021, USA

11 2 - Department of Computer Science and Electronic Engineering, University of Essex,
12 Colchester, CO4 3SQ, UK

13 3 - Department of Information and Communication Technologies, Universitat Pompeu Fabra,
14 08018, Barcelona, ES

15 4 - University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX
16 75390, USA

17 5 - VA North Texas Health Care System, 4500 S. Lancaster Rd., Dallas, TX 75216, USA

18 6 - Department of Psychiatry, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy
19 Place, New York, NY 10029-5674, USA

20

21 **Author Contributions:**

22 **VGF** and **DO**: Designed research, Performed research, Analyzed data, Wrote the paper. **BA** and

23 **XG** Analyzed data, Wrote the paper

24 **Correspondence should be addressed to (include email address)**

25 Vincenzo G. Fiore, vincenzo.g.fiore@gmail.com

26 Xiaosi Gu, xiaosi.gu@utdallas.edu

27 School of Behavioral and Brain Sciences, UT Dallas

28 800 W. Campbell Road, Richardson, TX 75080-3021, USA

29

30 **Number of Figures:** 5

31 **Number of Tables:** 5

32 **Number of Multimedia:** 1

33 **Number of words for Abstract:** 221

34 **Number of words for Significance Statement:** 107

35 **Number of words for Introduction:** 832

36 **Number of words for Discussion:** 1695

37

38 **Acknowledgements**

39 The authors thank Prof. Karl Friston for his comments and kind suggestions in shaping this
40 manuscript.

41

42 **Conflict of Interest**

43 Authors report no conflict of interest

44

45 **Funding sources**

46 This work is supported by the Dallas Foundation and a startup grant from UT Dallas.

47 **Abstract**

48 Addiction is characterized by a profound intersubject (phenotypic) variability in the expression
49 of addictive symptomatology and propensity to relapse following treatment. However, laboratory
50 investigations have primarily focused on common neural substrates in addiction and have not yet
51 been able to identify mechanisms that can account for the multifaceted phenotypic behaviors
52 reported in the literature. To fill this knowledge gap theoretically, here we simulated phenotypic
53 variations in addiction symptomology and responses to putative treatments, using both a neural
54 model, based on cortico-striatal circuit dynamics, and an algorithmic model of reinforcement
55 learning. These simulations rely on the widely accepted assumption that both the ventral, model-
56 based, goal-directed system and the dorsal, model-free, habitual system are vulnerable to extra-
57 physiologic dopamine reinforcements triggered by addictive rewards. We found that
58 endophenotypic differences in the balance between the two circuit or control systems resulted in
59 an inverted U-shape in optimal choice behavior. Specifically, greater unbalance led to a higher
60 likelihood of developing addiction and more severe drug-taking behaviors. Furthermore,
61 endophenotypes with opposite asymmetrical biases among cortico-striatal circuits expressed
62 similar addiction behaviors, but responded differently to simulated treatments, suggesting
63 personalized treatment development could rely on endophenotypic rather than phenotypic
64 differentiations. We propose our simulated results, confirmed across neural and algorithmic
65 levels of analysis, inform on a fundamental and, to date, neglected quantitative method to
66 characterize clinical heterogeneity in addiction.

67

68

69

70 **Significance statement**

71 Addiction is known to encompass heterogeneity in its development, maintenance, and treatment
72 response. While previous work has mostly focused on the common mechanisms underlying
73 vulnerabilities in addiction at a group level, the neurocomputational causes for such intersubject
74 variability in addiction are not well-understood. To fill this knowledge gap, we combine a neural
75 and a reinforcement learning model to reveal that the balance between neural circuits or
76 computational control modalities characterizes the presence of behavioral phenotypes in
77 addiction. The presence of converging effects, validated across neural and algorithmic levels of
78 analysis, informs on a quantitative method to characterize clinical heterogeneity, and potentially
79 helps future development of precision treatments.

80 **Introduction.**

81 Addiction is known to encompass a wide range of individual behavioral differences (i.e.
82 phenotypes) in development, maintenance and severity of symptoms, and treatment response
83 (Everitt and Robbins, 2016). Previous investigations into the mechanisms underlying this
84 heterogeneity of behaviors have identified two fundamental neurocomputational alterations
85 correlated with vulnerability in the development and severity of addictive behaviors (Garrison
86 and Potenza, 2014; Jupp and Dalley, 2014; Belin et al., 2016). These neural and computational
87 intersubject differentiations (i.e. endophenotypes) include 1) a dysregulation of D2 receptors in
88 the striatum (Morgan et al., 2002; Nader and Czoty, 2005; Dalley et al., 2007; Flagel et al., 2014)
89 and 2) an alteration of learning rates within a reinforcement-learning framework (Gutkin et al.,
90 2006; Piray et al., 2010). However, these endophenotypic differences are found across a wide
91 spectrum of dissociable phenotypes, so that the same neural or computational mechanism is used
92 to account for separable behavioral traits. For instance, different forms of striatal D2
93 dysregulation are found in individuals differing in terms of their impulsivity (Dalley et al., 2007;
94 Volkow et al., 2007), social dominance (Morgan et al., 2002; Gould et al., 2014), motor
95 reactivity or preference for novelty (Flagel et al., 2010; Flagel et al., 2014), or sensitivity to
96 rewards (Belcher et al., 2014). Each of these behavioral traits is separately correlated with
97 development of addiction, but they do not necessarily coexist in the same individuals (cf. novelty
98 seeking and impulsivity: Ersche et al., 2010; Molander et al., 2011; Belin and Deroche-Gamonet,
99 2012). This mismatch between few known endophenotypic differences and a wide variety of
100 multifaceted, dissociable, behavioral phenotypes suggests there are yet unknown neural and
101 computational mechanisms that are responsible, alone or in interaction, for the reported
102 behavioral differentiations. Finally, investigations into intersubject variability often emphasize

103 the initial stage of addiction development (but see e.g.: Belin et al., 2008; Economidou et al.,
104 2009; Pelloux et al., 2015). Yet, individual differences also exist in treatment response, resulting
105 in diverse relapse patterns among individuals showing similar severity of symptoms. These
106 differences have not been so far addressed in previous neural or computational models.

107

108 Here we propose a theoretical investigation into the interaction between ventral and dorsal
109 cortico-striatal circuits and the associated behavioral control modalities. Several studies have
110 emphasized that addiction is associated with alterations of ventral and dorsal cortico-striatal
111 circuits, and of motivations and habits (Volkow and Morales, 2015; Everitt and Robbins, 2016;
112 Koob and Volkow, 2016). However, the role played by the interaction between the two neural
113 circuits or between the two behavioral control modalities in generating intersubject variability in
114 addiction, has been so far neglected. To investigate this interaction, we use two models to
115 simulate neural dynamics and algorithmic (or normative) choice selections in a multiple-choice
116 task involving drug and non-drug rewards. Then we test these models under different conditions
117 of circuit or control modality dominance (i.e. simulated endophenotypes). Consistently with
118 previous models, we assume addictive substances hijack the healthy reward prediction error
119 signal (Schultz et al., 1997) by triggering extra-physiologic dopamine bursts (Nestler and
120 Aghajanian, 1997; Koob and Volkow, 2016). These dopamine activities signal the presence of an
121 aberrant unexpected reward, leading to the repetition of drug-related actions and escalation of
122 consumption (Redish et al., 2008; Dayan, 2009). In our neural model, this process of
123 reinforcement learning (RL, Sutton and Barto, 1998) is mediated by extra-physiologic changes in
124 cortico-striatal connectivity weights (Hyman et al., 2006; Haber, 2008; Koob and Volkow,
125 2016). These changes in turn aberrantly affect circuit gain and the stability of both ventral and

126 dorsal cortico-striatal circuits, disrupting their respective roles in encoding and selecting goal-
127 directed behaviors (Balleine, 2005; Balleine and O'Doherty, 2010; Gruber and McDonald, 2012)
128 and habitual responses (Yin et al., 2004; Balleine and O'Doherty, 2010). A similar effect is
129 assumed for our algorithmic model, where over-evaluation of drugs and related RL affect the
130 two control modalities, termed *model-based* and *model-free*, that approximate ventral/goal-
131 oriented and dorsal/habitual implementations (Dolan and Dayan, 2013; Voon et al., 2017). As a
132 result, and consistently with previous formulations of RL models of addiction (Redish et al.,
133 2008; Piray et al., 2010; Gillan et al., 2016), both the planned evaluation of known action-
134 outcome contingencies, represented in an *internal model* of the world, and the reactive
135 immediate motor responses are biased towards drug-related selections.

136

137 Based on these assumptions, our models show that phenotypic differentiation in addiction
138 development and treatment response can emerge as a function of the interaction between ventral
139 and dorsal circuits or model-based and model-free control modalities. Our simulated results offer
140 a proof-of-concept that this interaction is a candidate independent neural and computational
141 mechanism underlying addiction vulnerability, putatively characterizing three different
142 endophenotypes differing in the likelihood to develop addiction, severity of symptoms and
143 treatment response. We suggest this neurocomputational mechanism could interact with both
144 previously described D2 receptors dysregulation in the striatum (Dalley et al., 2007; Flagel et al.,
145 2014) and altered learning rates (Gutkin et al., 2006; Piray et al., 2010) to generate the variety of
146 dissociable behavioral traits reported in literature as associated with addiction vulnerabilities.

147

148 **Materials and Methods.**

149 In brief, we present two complementary models simulating endophenotypic differences and their
150 effects on addiction development and treatment response. In the models, intersubject differences
151 are expressed in terms of either neural circuit dominance (i.e. ventral or dorsal circuit) or control
152 modality dominance (i.e. model-based or model-free) in determining behavioral selections. The
153 resulting phenotypes are tested in environments granting free access to a simulated substance of
154 addiction, as usually implemented in laboratory studies. In particular, we compare our simulated
155 phenotypic variability with the results described in a recent study investigating individual
156 differences in rats self-administrating the stimulants cocaine or a designer drug, a dopamine- and
157 mixed dopamine-norepinephrine reuptake inhibitor, respectively (Gannon et al., 2017). We
158 selected this study because it highlights how different drugs, dosages, and tasks result in different
159 ranges of phenotypic differentiation. For instance, an initial acquisition phase, over a 10-day
160 period, shows compulsive behavior developed in up to 75% rats self-administering cocaine and
161 87.5% of those exposed to the designer drug. Furthermore, under a condition of fixed ratio (=5)
162 schedule, the study shows self-administration varied significantly among subjects. A subset of rat
163 population, termed high responders, self-administered cocaine up to 60% more times in
164 comparison with a different subset, termed low responders, depending on dosage (cf. figure 3 in:
165 Gannon et al., 2017). Importantly, the task setup chosen for both of our proposed models
166 involves the selection of a drug reward over explicit non-drug related alternatives; in contrast,
167 the chosen empirical study utilizes a time-out responding paradigm, where the only explicit non-
168 drug related behavior (a lever-press) is not rewarded. As for most studies simulating addiction
169 (e.g. see: Redish, 2004), we believe the choice to present our simulated agents with a richer set
170 of options (i.e. more than one) does not invalidate a parallel between simulated and real data. We
171 consider the simulated competing options as a proxy for the many conflicting stimuli and

172 associated behaviors that animals have access to, even in the limited environment of a standard
173 operant conditioning chamber. Thus, our focus is on perturbing the balance between the
174 dorsal/model-free and the ventral/model-based systems, to compare our simulated behavioral
175 differentiations in the escalation and compulsive selection of drug-related actions with the data
176 reported in the chosen laboratory study.

177

178 The two models comprise a neural mass model that has been validated and described in the
179 context of choice behavior and dopaminergic modulation (Fiore et al., 2016; Hauser et al., 2016;
180 Fiore et al., 2018) and a normative or algorithmic model based upon standard RL schemes
181 (Sutton and Barto, 1998). In the neural model, addiction and treatment response are modeled
182 through DA-dependent associative plasticity in both ventral and dorsal circuits. In the RL model,
183 aberrant learning is modeled using a duplex of model-based and model-free schemes that
184 competed for control over action selection. The model-based scheme entails learning a model of
185 the environment (in the form of probability transition matrices among states) that is used to
186 compute value functions under the Bellman optimality principle (Bellman, 1966). The equivalent
187 model-free scheme uses prediction error-based learning to directly acquire the value of state
188 action pairs. Both neural and RL models are tested under four successive stages or phases; 1)
189 before exposure to the simulated drug (termed *pre-drug*); 2) learning of addictive behavior
190 (termed *addiction*); 3) simulated ideal therapeutic interventions (termed *treatment*) that partially
191 revert the learning of the previous phase. Finally, 4) reinstated access to the simulated drug
192 following each treatment (termed *relapse*). The simulated treatments are conceived to emphasize
193 endophenotypic response and relapse differentiation and therefore they predominantly affect
194 only one control system, targeting either the goal-oriented/model-based or the habitual/model-

195 free. The former treatment is assumed to modify only the internal model of the environment and
196 related selection of action-outcome contingencies performed in the ventral circuit. The latter
197 treatment represents a condition in which the model of the world of the agent remains mainly
198 unaltered, but the acquired drug-related stimulus-response associations are disrupted, thus
199 preventing the agent from exhibiting habitual responses (cf. Doll et al., 2009).

200

201 The unique aspect of this complementary modeling approach is that converging results from
202 neural and algorithmic models can validate each other, as process and implementation theories
203 (i.e., synaptic and dynamical mechanisms) complement the normative principles formalized in
204 the RL model.

205

206 **Neural field model.**

207 *Basic model architecture and parameterization:* In cortico-striatal circuits, the signal processed
208 in the cortex is conveyed towards its respective area of the striatum, processed in basal ganglia
209 and finally relayed to the same cortical area where it originated, via thalamus (Haber, 2003;
210 Draganski et al., 2008; Jahanshahi et al., 2015). Thus, despite diverging in terms of the
211 information processed –e.g. sensorimotor or rewards and outcomes– these circuits are
212 characterized by similar computational dynamics (Obeso et al., 2014). Temporal responses in
213 recurrent neural networks co-occur with state transitions or input transformations that are often
214 described in terms of energy landscapes (**Figure 1A-C**). If multiple inputs or initial states
215 generate transitions towards the same final state, this is termed *attractor state* (Amit, 1989). In
216 recurrent networks such as cortico-striatal circuits, learning processes modulate the circuit gain,

217 thereby affecting the strength of the attractor states and the overall stability of the system (Fiore
218 et al., 2015; Fiore et al., 2016; Hauser et al., 2016).

219

220 We simulate the temporal responses in cortico-striatal circuits in a neural model (illustrative
221 representation of the neural architecture is represented in **Figure 1D**). This neural model
222 simulates mean-field activity (Deco et al., 2008) within multiple channels of both dorsal and
223 ventral cortico-striatal loops. A continuous-time differential equation simulates changes over
224 time (τ_g) of the average action potential (u_j) of a pool of neurons (equation 1), and a positive
225 transfer function (equation 2) converts this action potential in the final activation of the pool (y_j).
226 Finally, the plasticity of the connections (w_{ij}) between cortex and striatum is characterized by
227 DA-dependent Hebbian learning, corrected with a constant threshold (th) as defined in equation
228 3. The resulting rule strengthens the connections among all active nodes in the cortex and those
229 active in the striatum, and weakens the connections among nodes showing opposite activation
230 status.

231

$$232 \quad \tau_g \dot{u}_j = -u_j + b_j + (\epsilon + \lambda d) \sum w_{ji} y_i \quad (1)$$

$$233 \quad y_j = [\tanh(u_j - \theta)]^+ \quad (2)$$

$$234 \quad \Delta w_{ij} = \eta \left([y_i - th]^+ [y_j - th]^+ [d - th]^+ \right) - \zeta \left([th - y_i]^+ [th - y_j]^+ [d - th]^+ \right) \quad (3)$$

235

236 The input ($\sum w_{ji} y_i$), reaching each node in the neural network is modulated by two coefficients λ
237 and ϵ . These regulate the ratio between the signal affected by the presence of dopamine release d
238 and the amount of signal that is computed independent of dopamine release. For most units, the
239 values of the two coefficients are set to $\lambda = 0$ and $\epsilon = 1$, with the exception of the simulated

240 striatal units, where these parameters are set to $[\lambda = 1.4, \epsilon = 0.2]$ and $[\lambda = -0.5, \epsilon = 0.6]$, to
 241 simulate the differential effect dopamine has, depending on the most prevalent receptor type
 242 ($\lambda > 1$ and $\lambda < 0$ for D1 and D2 receptors, respectively). Due to the different effects the dopamine
 243 receptors have on the activity of the simulated neurons, the drug-induced dopamine-dependent
 244 Hebbian learning significantly affects D1-enriched units in the striatum, whilst having negligible
 245 effects on D2-enriched units (Gerfen and Surmeier, 2011; Volkow and Morales, 2015).

246
 247 *Simulating different addiction phenotypes and treatment effects:* Agents controlled by the neural
 248 model are immersed in a simplified environment and can select among three arbitrary actions or
 249 inactivity (cf. non-stationary three armed bandit environment). The selection of the actions is
 250 carried out in the circuit simulating the dorsal cortico-striatal activity and it is considered
 251 completed if the neural activity of any of the units in the external layer of the simulated cortex
 252 (cf. **Figure 1D**) is maintained for at least 2 seconds. Ventral and dorsal circuits interact, both
 253 ways, via cortico-cortical connectivity. Therefore, the activity in the simulated ventral circuit
 254 biases action selection in the dorsal circuit and the selection of actions in the dorsal circuit biases
 255 the activity in the ventral circuit. To test our hypothesis about the effect these reciprocal biases
 256 have on choice behavior, we assumed cortico-cortical weights do not vary over time and we
 257 tested eleven combinations for the parameters determining their weights, as $w_{ji} = [0.02-0.2]$,
 258 $[0.03-0.17]$, $[0.03-0.15]$, $[0.05-0.15]$, $[0.07-0.13]$, or $[0.1-0.1]$ (and symmetrical). This spectrum
 259 of weights describes the strength of the biases between the two major circuits, thereby
 260 characterizing either a balanced condition or a dominance of one of the two circuits. We report
 261 the effects in terms of behavioral responses for these putative endophenotypes and test each of
 262 these with thirty noise seeds, random inputs and under four stages, to allow within phenotype

263 comparisons. The first stage, “pre-drug”, represents an assessment of behavior before any drug
 264 or reward is introduced, as the three available inputs randomly change their value to determine a
 265 non-stationary order of preferences. Under the second stage, termed “addiction”, one action is
 266 associated with the administration of a simulated addictive substance, triggering DA phasic
 267 responses and associated Hebbian learning in cortico-striatal connections of both ventral and
 268 dorsal circuits. For the third stage, termed “treatment”, we simulate the effects of deprivation
 269 coupled with one of two hypothetical treatments targeting either the dorsal or the ventral cortico-
 270 striatal circuits. The treatments are simulated by reverting the learning process in either the
 271 dorsal or the ventral cortico-striatal circuit, respectively representing an intervention that would
 272 block or extinguish either the habitual drug-related response (an ideal behavioral treatment) or
 273 the drug-related emotional and value association (an ideal cognitive treatment). The dorsal
 274 treatment brings back the pre-drug configuration in the dorsal circuit and keeps the configuration
 275 reached under the addiction stage for the ventral circuit. The ventral treatment is achieved with
 276 the opposite intervention. Finally, during the fourth stage, termed “relapse”, we reintroduce
 277 access to the simulated addictive substance, inducing relapse. For this stage, relapse time is
 278 defined as the time required to reinstate the configuration of cortico-striatal weights found at the
 279 end of the *addiction* stage.

280

281 **RL model.**

282 *Basic model architecture and parameterization:* In this model, we assume that the behavior of
 283 the agent relies on a hybrid model (Daw et al., 2011) that learns and computes the value of
 284 choices (actions, a_t) under each condition (state, s_t). Value is defined as a quantity that combines

285 short and long term expected rewards and negative outcomes when a specific strategy of action
 286 is followed (policy, π). It is formally defined as:

287

$$288 \quad Q^\pi(s_t a_t) = r(s_t a_t) + E\left[\sum_i \gamma^i r(s_{t+i}, a_{t+i} = \pi(s_{t+i})) | s_t, a_t\right] \quad (4)$$

289

290 In equation (4), $r(s, a)$ denotes the instantaneous reward received when action a is performed in
 291 state s . γ is a discount factor, comprised between 0 and 1, which defines the trade-off between
 292 immediate and long term rewards. The value of a state given the policy is defined as $V^\pi(s) =$
 293 $\max_a Q^\pi(s, a)$. For each environment there is an optimal policy $\pi^*(s)$, which maximizes the
 294 value $V^{\pi^*}(s)$ for every state (Sutton and Barto, 1998).

295

296 The environment can be completely characterized through the state transitions distributions
 297 $p(s_{t+1} = s | s_t, a_t)$, and the expected rewards $E(r | s, a) = R(s, a)$. These two functions together
 298 represent a model of the environment. Model-based behaviors compute $Q^\pi(s_t a_t)$ and the policy
 299 relying on such functions, at each state, following the Bellman equation (Daw and Dayan, 2014):

300

$$301 \quad Q^{\pi^*}(s_t, a_t) = R(s_t, a_t) + \gamma \sum_s \left[p(s_{t+1} = s | s_t, a_t) \max_a Q^{\pi^*}(s, a) \right] \quad (5)$$

302

303 The model-based component learns the transition distributions and the expected rewards during
 304 the interaction with the environment. Thus, differently from other hybrid models (Daw et al.,
 305 2005; Keramati et al., 2011; Pezzulo et al., 2013), the quality of Q value estimation at any given
 306 moment depends on the experience the agent acquired up to that point in time. To compute value
 307 estimation (Q_{MB}), this bounded (Gershman et al., 2015) component applies at each step the

308 Bellman equation (5) a limited number of times ($N_{PS} = 50$) to states sampled stochastically
309 following a heuristic for efficient state update selection. The algorithm is an early-interrupted
310 variation of the Prioritized Sweeping algorithm (Moore and Atkeson, 1993) with stochastic state
311 update selection. Crucially, our model-based component does not accumulate the variations of Q
312 values over time, and restarts the computation after each step (desJardins et al., 1999). This
313 choice is meant to instate a plausible bounded rationality for our model which can account for
314 the cognitive costs and ensuing limits of integrating old and new information about the
315 environment, whilst updating and extending a complex plan to navigate it. This implementation
316 is suitable for a bounded rational model-based component that shows controlled stochasticity of
317 deliberation performances in non-trivial environments. This choice allows to test the effects of
318 the hypothesized endophenotypic differentiation in an environment characterized by higher
319 degree of complexity in comparison with both the one chosen for the neural model and those
320 described in the literature of RL models of addiction. In particular, we consider drug
321 consumption to be associated with complex after-effects that make it difficult to predict the
322 overall result of pursuing the related action course.

323

324 In comparison with other hybrid models such as Dyna and Dyna2 (Sutton, 1990; Silver et al.,
325 2016), the proposed architecture does not share Q values between model-based and model-free
326 components, nor it requires that the two processes share the same state representations. The two
327 components separately represent their Q values and integrate them in a later phase. This
328 decoupling is assumed to result in a more biologically plausible agent (Daw & Dayan 2014), and
329 it is essential for the simulations of two separate treatments, essential requirement to establish a
330 comparison with the behavior simulated with the neural model. In contrast with previous work

331 using a hybrid Dyna-like architecture and Prioritized Sweeping algorithm, where the sharing of
 332 the Q-values explained the appearance of model based drug oriented behavior (Simon and Daw,
 333 2012), in our simulations this model based addiction emerges in independent model-free and
 334 model based components. Thus, addiction behavior results from the joint effect of high reward
 335 (i.e. the drug), a limited number of stochastically selected policy updates and limited knowledge
 336 of the environment.

337

338 The model-free component has been implemented using the Q-Learning algorithm in tabular
 339 form (Watkins and Dayan, 1992). Q-learning updates initial state value estimations as follows:

340

$$341 \quad Q_{MF}(s_t, a_t)_{new} = Q_{MF}(s_t, a_t)_{old} + \alpha \delta_t \quad (6)$$

$$342 \quad \delta_t = R(s_t, a_t) + \gamma \max_{a'} [Q_{MF}(s_{t+1}, a')] - Q_{MF}(s_t, a_t) \quad (7)$$

343

344 where α is a learning factor comprised between 0 and 1. Our hybrid model computes choice
 345 values in a fashion that balances model-free (MF in the equations) and model-based (MB in the
 346 equations) components depending on a parameter β . Six values (1, 0.8, 0.6, 0.4, 0.2, 0) are used
 347 for this parameter to simulate different endophenotypes, on a spectrum between purely model-
 348 based ($\beta=1$) and purely model-free ($\beta=0$) RL.

349

350 To allow exploration, the action to execute is selected randomly 10% of the times. This
 351 exploration factor is kept constant to support adaptation to a changing environment (Singh et al.,
 352 2000) and to simulate the continuous update of knowledge necessary to cope with ecological
 353 environments. The remaining 90% of the times, actions are determined by maximizing $Q_{MX}(s,a)$

354 in a strategy defined as ϵ -greedy ($\epsilon=.1$). These values are produced by combining the values
 355 computed by the model-based and model-free components:

356

$$357 \quad Q_{MX}(s, a) = \beta Q_{MB}(s, a) + (1 - \beta) Q_{MF}(s, a) \quad (8)$$

358

359 The choice for a fixed balance between model-based and model-free requires minimal
 360 assumptions on their interaction and has been used in recent reinforcement learning architectures
 361 (Silver et al., 2016).

362

363 *Simulating different addiction phenotypes and treatment effects:* In comparison with the
 364 simulations characterizing the neural model, a more complex environment is in use for the RL
 365 model to highlight how our endophenotypic differentiations can also affect the likelihood to
 366 develop addiction. This environment is characterized by a total of 20 states divided into four
 367 different types (**Figure 2**): (i) healthy rewards (i.e. normal rewards that are not directly
 368 associated with drugs); (ii) neutral states (no reward or negative outcome); (iii) drug-related
 369 states, which give a high reward but are followed by multiple (iv) drug aftereffects, characterized
 370 by small negative outcomes. Similar to the neural model investigations, the agent deals with
 371 environment variations meant to simulate four phases of addiction: initial pre-drug phase (f1);
 372 addiction (i.e. the drug becomes accessible for the first time, f2); treatment (f3); relapse (i.e.
 373 second drug exposures, f4). Under the initial pre-drug phase ($d_{init}=50$ steps), the agent does not
 374 receive any reward or negative outcome by entering the drug-related and aftereffects area, but a
 375 moderate reward is assigned ($R_g=1$) by accessing the healthy reward state. Under the phases of
 376 addiction and post-treatment addiction ($d_{tpy}=1000$ steps), the agent can also receive a high

377 reward, after accessing a drug-related state ($R_d=10$). The drug state always leads to a series of
 378 randomized state transitions among the aftereffects states ($R_a=-1.2$) and simulates generic
 379 negative consequences associated with addiction. The agent can occasionally leave this
 380 aftereffect area of the environment (**Figure 2**) to reach a neutral state, at the price of a further
 381 negative outcome ($R_a=-4$). Under the treatment phase ($d_{tpy}=1000$ steps), the drug-related state
 382 results in a negative outcome ($R_{dt}=-1$, see **Tables 1** and **2**, column f3), thus increasing the
 383 chances the agent stops pursuing this state. To allow for a comparison with the results in the
 384 neural model, we simulate a model-based and model-free treatment by manipulating the learning
 385 factor of the non-treated control modality, decreasing it: $\alpha_{Ctpy}=0.01 * \alpha$. Under the relapse phase,
 386 we measure the simulated time required by the agents to reach at least 95% of drug-related action
 387 preference as recorded under the addiction phase, after the drug is introduced again in the
 388 environment. This threshold is used to measure the percentage of agents relapsing, as well as the
 389 time required to complete the relapse, per endophenotype.

390

391 **Code Accessibility**

392 All models rely on custom code developed in Matlab (optimized for R2014b) that has been run
 393 successfully on multiple OS (iOS, Linux and Windows) on different computers and local servers.
 394 The code can be accessed at any time from the repository ModelDB (accession number: 239540;
 395 <https://senselab.med.yale.edu/modeldb/enterCode.cshhtml?model=239540>; title: ‘Computational
 396 Endophenotypes In Addiction: Source Code’). The downloadable archive file consists of two
 397 folders (respectively for the neural model and the RL model), which include the entire source
 398 code required to replicate the data reported in our Results section. Code available as Extended
 399 Data 1.

400

401 **Results.**402 **Simulations from the neural field model.**

403 During all stages, the three stimuli randomly change every few seconds, putatively representing a
404 dynamic fluctuation of values associated with perceived cues in a non-stationary environment.
405 This setup requires the agents to rapidly adapt to these changes, transiently triggering the motor
406 response associated with the most valuable cue, in order to achieve optimal behavior. During the
407 pre-drug stage, dorsal and ventral circuits perform unbiased selections, collaborating in the
408 generation of a near-optimal sequence of motor selections. All eleven endophenotypes show
409 uniform distributions of action selections, complying with the random distribution of the inputs
410 configurations (**Figure 3A**). This control stage allows the simulated network to generate
411 transient temporal responses that couple multiple initial states with multiple stable states, in a
412 transient *winner-take-all* or *winner-less* competition (Rabinovich et al., 2006; Afraimovich et al.,
413 2008).

414

415 During the simulated addiction stage, one of the actions is associated with drug administration
416 (**Figure 3B**, values represented in blue). Substance use triggers phasic dopamine bursts, leading
417 to Hebbian learning in cortico-striatal connections of both dorsal and ventral circuits (equation
418 3). In recurrent networks, circuit gain increases as a direct function of the weights of reentrant
419 synapses (Amit, 1989). A dopamine response triggered by healthy unexpected rewards would
420 create a bias towards the selection of the reinforced motor response to a perceived cue (Cohen
421 and Frank, 2009; Grahn et al., 2009; Baldassarre et al., 2013). However, drug consumption
422 triggers extra-physiologic dopamine-dependent learning, which in our model results in aberrantly

423 high circuit gain, compromising the ability of all affected circuits to discriminate among different
424 inputs and produce temporal transitions towards multiple stable states (cf. Fiore et al., 2014). The
425 cortico-striatal circuits become over-stable and resistant to perturbation caused by a change of
426 input or by noise as they are dominated by *parasitic attractors* (Hoffman and McGlashan, 2001)
427 (**Fig 1C**). In the ventral cortico-striatal circuit, a parasitic attractor sets and maintains the
428 selection of drug-related goals or outcomes, biasing the action-outcome assessments required for
429 planning. In the dorsal circuit, the same process determines over-stable selections of the
430 reinforced motor behavior, generating reactive responses and habits. Importantly, the learning
431 process simulated in our neural model leads to the generation of parasitic attractors in both
432 circuits across all endophenotypes, as all agents eventually reach a fixed threshold in cortico-
433 striatal neural plasticity. Despite the generation of a form of compulsive drug seeking behavior
434 across all endophenotypes, we observe significant differences in motor response patterns as a
435 function of the balance between ventral and dorsal circuits. Specifically, the endophenotypes
436 characterized by unbalanced dorsal or ventral control (i.e. **Figure 3B**, endophenotypes 1-3 and 9-
437 11) express distributions of motor selections that are significantly more compromised by drug-
438 related aberrant rewards, in comparison with balanced endophenotypes (i.e. **Figure 3B**,
439 endophenotypes 5-7). The presence of identical learning processes, and the associated attractor
440 formation in both ventral and dorsal circuits, ascribes all phenotypic differences univocally to the
441 only remaining independent variable, which controls cortico-cortical connectivity and therefore
442 the strength of the biases between circuits. Unbalanced agents are characterized by more frequent
443 drug-related selections as actions leading to drug consumption are selected more frequently than
444 in balanced endophenotypes, in a range between +3% and +45%. This result identifies all

phenotypes within the limits of individual differentiation described in the study chosen for behavioral comparison (Gannon et al., 2017).

Next, we investigate how the simulated endophenotypes behave during the stages of treatment and relapse. First, we measure the frequency of drug-related action selections during the stages of addiction and treatment (**Figure 4A-B**). Both ventral (goal-oriented) and dorsal (habitual) treatments effectively reduce the number of actions associated with drug consumption, in comparison with baseline addiction. However, the dorsal treatment is more effective for dorsal-dominated endophenotypes and the ventral treatment is more effective for ventral-dominated endophenotypes. These endophenotype-specific treatment effects are further confirmed by our analysis of individual differences under the relapse stage (**Figure 4C-D**): dorsal treatments are more effective in elongating time to relapse for dorsal-dominated endophenotypes, whereas ventral treatments are more successful in delaying relapse for ventral-dominated endophenotypes. This analysis shows that simulated treatments focusing either on the dorsal circuit (and therefore habitual responses) or the ventral circuit (and therefore motivational responses) can have substantially different effects, depending on the balance between dorsal and ventral circuits. Importantly, these differences emerge only after the treatment is applied, where a pre-treatment comparison between compulsive behaviors expressed by the opposite unbalanced endophenotypes (i.e. ventral-dominant or dorsal-dominant) does not show any significant difference in choice selections (cf. **Figure 3B**, endophenotypes 1-3 and 9-11).

Simulations from the RL model.

467 By simulating explicit negative outcomes associated with drug consumption, the RL model
468 allows to measure the likelihood each agent has to develop addiction, as a function of its
469 endophenotype. In our analysis, addiction is defined as a behavior leading to drug selections
470 more frequently than the healthy alternative reward, under the addiction phase. The mean
471 percentage of these *addicted* agents (over 300 runs) was 43.05%, across endophenotypes, which
472 is consistent with the percentage of rats developing compulsive self-administration of cocaine, as
473 reported in the reference study (~40% over a period of 5 days, cf. Gannon et al., 2017).
474 Importantly, when considering endophenotype differentiation, the percentage varies
475 significantly: 60.3% for $\beta = 0$, 40.3% for $\beta = 0.2$, 30.1% for $\beta = 0.4$, 36.7% for $\beta = 0.6$, 39.3% for
476 $\beta = 0.8$, and 51.6% for $\beta = 1$ (**Figure 5A-B**). This phenotypic differentiation is consistent with
477 well-established data from animal models. For instance, rat strains selectively bred for either
478 high or low voluntary running differ in the likelihood to develop addiction when given free
479 access to cocaine (respectively ~35% and ~60% of each strain develop addiction over a period of
480 5 days, cf. Smethells et al., 2016). Free access to substances of abuse does not necessarily lead to
481 compulsive behaviors (Piazza et al., 1989; Belin et al., 2011), as addiction varies as a function of
482 factors such as exposure extent, amount of drug delivered, and associated negative effects
483 (Pelloux et al., 2007; Jonkman et al., 2012). Our simulations suggest that endophenotypes with
484 lower chances of addiction are characterized by balanced control modalities. Note that an
485 optimal agent, knowing the environment structure and being able to compute the long-term
486 effects of drug, will never select drug-states (**Table 3**).

487

488 Finally, the simulations suggest that the hypothetical treatment targeting model-free control is
489 the most effective, reducing the likelihood to pursue drug-related behaviors for all

endophenotypes (**Figure 5A**). In contrast, the model-based treatment appears to be less effective for all endophenotypes, with the exception of the purely model-based one ($\beta=1$) (**Figure 5B**). Under the relapse phase, our data confirm that the simulated treatments significantly differ in their effectiveness across the proposed endophenotypes, also suggesting the treatment targeting model-free control is the most successful in prolonging relapse time (**Figure 5C-D**). Relapse time after model-free treatment is mostly similar to the time required to develop addiction behavior before any treatment (**Figure 5C**). At the opposite side of the control spectrum, the model-based treatment shows a positive effect only for the purely model-based endophenotype. All remaining endophenotypes show relapse times significantly shorter than those recorded for the first development of addiction ($\beta=1$; **Figure 5D**).

Discussion

Individual differences in stress and anxiety responses (Dilleen et al., 2012; Jimenez and Grant, 2017), social dominance (Morgan et al., 2002; Covington and Miczek, 2005), aggressive temperament (McClintick and Grant, 2016), preference for saccharine (Carroll et al., 2002), sensation or novelty seeking (Suto et al., 2001; Nadal et al., 2002; Belin et al., 2011; Flagel et al., 2014), impulsivity (Perry and Carroll, 2008; Verdejo-Garcia et al., 2008; Dalley et al., 2011), and sensitivity to rewards (Belcher et al., 2014) have all been found in both animal models and clinical studies in humans to be associated with addiction vulnerabilities, and in particular with the likelihood to develop and maintain addiction, or to resist to treatment (Piazza et al., 1989; Belin et al., 2016; Everitt and Robbins, 2016). However, investigations into the mechanisms underlying this phenotypic differentiation in addiction has so far revealed few neural or computational candidates, which are found to be associated with diverse and dissociable

513 behavioral traits. An important example is represented by the endophenotypic differentiation
514 reported in the expression and reactivity of striatal D2 dopaminergic receptors, which is found to
515 be negatively correlated with the traits of impulsivity (Dalley et al., 2007), social dominance
516 (Morgan et al., 2002), and sensitivity to rewards (Belcher et al., 2014) and non-linearly
517 correlated with novelty preference (Flagel et al., 2014). The overlap of this endophenotypic trait
518 across multiple, non-coexisting, phenotypes associated with addiction vulnerabilities suggests
519 other neural or computational mechanisms have yet to be identified to allow accounting for the
520 reported variety in behavioural traits.

521

522 Here we have presented a neural field model, augmented by an RL model, to expand on existing
523 neuropsychological and computational accounts of addiction. Our models propose a theoretical
524 investigation into the interaction among cortico-striatal circuits or behavioral control modalities,
525 and the effects this interaction has on addiction development and treatment response. As
526 described in classic models (Redish, 2004; Redish et al., 2008; Dayan, 2009), we have assumed
527 that over-evaluation of a drug leads to aberrant dopamine release and associated over-learning in
528 multiple DA targets (Volkow and Morales, 2015; Koob and Volkow, 2016). In the neural field
529 model, this mechanism results in the dysregulation of the circuit gain and associated dynamics of
530 both ventral and dorsal cortico-striatal circuits (Fiore et al., 2014; Hauser et al., 2016). In the
531 integrated model-based and model-free RL model, sequential choice behavior is confounded by
532 the presence of a high immediate reward (drug state). This leads to misrepresent the negative
533 outcomes following drug consumption, if their distribution across states and time is sufficiently
534 complex to escape the capabilities of the agent to correctly represent the environment (Doll and
535 Daw, 2016; Sadacca et al., 2016). We found that both models jointly indicate that the balance

536 between neural circuits or behavioral control modalities is a candidate neurocomputational
537 mechanism characterizing endophenotypes in addiction. The neural and RL models converge in
538 suggesting that individuals characterized by balanced behavioral control between reward-seeking
539 or planning (ventral circuit/model-based) and reactive or habitual responses (dorsal
540 circuit/model-free) would have a reduced chance to develop addiction and decreased severity of
541 symptoms if developing addiction. We propose that this neurocomputational mechanism may be
542 interacting with other known endophenotypic differentiations, such as alterations of D2 receptors
543 in the striatum (Morgan et al., 2002; Nader and Czoty, 2005; Dalley et al., 2007; Volkow et al.,
544 2007; Belcher et al., 2014; Flagel et al., 2014) or differences in learning rates (Gutkin et al.,
545 2006; Piray et al., 2010), to generate the multifaceted behavioral traits that have been reported in
546 literature to be associated with addiction vulnerabilities.

547

548 In our neural model, ventral and dorsal circuits are mostly in phase in their selections under the
549 pre-drug stage, exhibiting synchronous transient stability of neural activity and enhancing the
550 overall ability of the system to adapt to changing stimuli (i.e. the two circuits adapt to the input
551 changes with a similar pace and synchronize in their selection). Under the addiction stage, the
552 two circuits are mostly pulled towards the parasitic attractor state associated with drug
553 consumption, and they occasionally select the competing non-drug stimuli. If only one of the two
554 systems performs a selection outside of the attractor, the difference in selection generates a
555 dissonance or interference. In neural endophenotypes characterized by unbalanced control, this
556 dissonance is solved by one circuit taking the lead, so that both systems eventually converge on
557 the selection of the dominant circuit. These dynamics result in limited opportunities to generate
558 non-drug related responses to the external stimuli, as they can only be generated by the dominant

559 circuit. Conversely, in balanced control endophenotypes, if any of the two circuits ignores the
560 drug-stimulus and selects a competing option, the resulting dissonance can trigger a state
561 transition pulling out the parasitic attractor states associated with substance use. The
562 endophenotypes in our simulations vary only in the parameters regulating the balance between
563 circuits, as dopamine-driven learning processes established between cortex and striatum
564 (equation 3) do not vary across endophenotypes, resulting in identical habit formation and drug-
565 related biases in the outcome representations. Thus, our proposed phenotypic differentiation does
566 not interfere with the usual role ascribed to the ventral and dorsal circuits as respectively
567 implicated in the initial reward-seeking phase in addiction (Belin and Everitt, 2008; Willuhn et
568 al., 2012) and the subsequent consolidation of stimulus-response, habitual, association (Everitt
569 and Robbins, 2013, 2016). However, our simulated dynamics show that, after addiction is
570 developed, systemic over-stability can be reduced or further enhanced, depending on the cortico-
571 cortical biases between cortico-striatal circuits. In turn, this modulation of system stability can
572 foster or further impair input discrimination and motor response versatility, affecting addiction
573 symptomatology. As a result, our neural model shows phenotypic variability emerging after the
574 presentation of the reward simulating the drug and addiction is developed, in a gradient of over-
575 selection of drug-related actions.

576

577 With the RL model, we investigate whether the balance between model-based and model-free
578 modalities would also increase the robustness of the system against the selection of drug-states in
579 a more complex environment and in presence of explicit negative outcomes. Similar to the neural
580 model, a system with balanced control modalities introduces more diversity in action selection
581 during exploration, reducing (yet not cancelling) the chances of developing maladaptive reactive

582 responses. This increased diversity and overall reliability are likely to be induced by a higher
583 redundancy and diversification of the system. While both components may fail, the causes of
584 failures are not necessarily correlated. The model-based system can fail due to its sensitivity to
585 cognitive resources but it is more efficient in encoding previous experience of the agent. On the
586 other hand, the model-free component is affected by limited exploration but it is reliable in its
587 selections, which are not affected by the availability of cognitive resources. Consistent with the
588 neural model, differentiations in behaviors among endophenotypes emerge in an inverted-U
589 shape, where unbalanced control system are the most vulnerable to developing addiction.

590

591 The phenomenon of relapse is more elusive and the two models do not fully converge on this
592 aspect. To investigate this phenomenon, we have adapted the complexity of real world
593 treatments to the capabilities of our simulated agents and environments, where we can easily
594 manipulate or extinguish consolidated memory, but we cannot engage all other aspects
595 commonly involved in addiction treatment, such as cognitive or emotional functions or
596 developing new behavioral strategies to compete with drug-related habits. Therefore, we
597 implemented two compartmentalized treatments that we consider as ideal reference models that
598 target only a single decision system or circuit. These putatively represent treatments capable of
599 affecting only drug-related emotional/value or habitual/motor associations. In the neural model,
600 balanced dorsal and ventral endophenotypes respond well to both types of simulated treatments.
601 For the unbalanced endophenotypes, however, only the appropriate treatment, targeting the
602 dominant neural circuit, is effective. The simulations in the RL model do not show the same
603 symmetric effects for the two treatments: the model-free treatment is effective for most
604 endophenotypes, whereas the model-based treatment is mostly unsuccessful, with short relapse

605 times across all endophenotypes, but the purely model-based one. The latter result is possibly
606 due to the learning process characterizing the model-based component, which is affected by
607 conflicting information as drug use is associated with both positive and negative outcomes,
608 experienced by the agent when entering the drug state under different phases.

609

610 It is worth noting that habitual and goal-oriented behaviors have neural representations in the
611 dorsal and ventral cortico-striatal circuits respectively, but they do not fully overlap with model-
612 based and model-free control modalities in RL (Dolan and Dayan, 2013). Nonetheless, the neural
613 and RL models independently simulate choices among competing options in addiction. Thus, we
614 have been able to test our hypothesis of endophenotypic differentiation under two
615 complementary levels in Marr's tri-level of analysis: the neural implementation and the
616 algorithmic level (Marr and Poggio, 1976). This multilevel modeling approach has been often
617 used in computational psychiatry (Maia and Frank, 2011; Montague et al., 2012; Adams et al.,
618 2016; Hauser et al., 2016; Huys et al., 2016) to highlight model convergence and associate
619 specific neural structure and dynamics with mathematical formalizations of optimal and
620 suboptimal behavior in RL. The convergence of neural and RL models on important predictions
621 also provides more confidence in the reliability of the identified computational mechanisms
622 underlying addiction and the associated characterization of endophenotypes. Specifically, both
623 models indicate individuals with unbalanced cortico-striatal activity or control modality are at
624 higher risk of developing addiction and relapse after any treatment. Thus, independent of
625 phenotypic-specific treatments, our results suggest that individuals with these traits would
626 require a prolonged or more intense treatment, in comparison with balanced endophenotypes.
627 Finally, when considering phenomena that are divergent across both models (e.g. **response**

628 across endophenotypes to our simulated treatments), our findings still demonstrate that important
629 endophenotypic features might remain undetected in terms of pre-treatment observable behavior.
630 The models showed that opposite unbalanced agents resulted in similar addictive behaviors and
631 vulnerabilities, but diverged in treatment response, potentially informing the development of
632 precision interventions. Further studies will be required to provide empirical validation of our
633 models. For example, computational analysis of fMRI data can be used to test effective
634 connectivity among cortico-striatal circuits (e.g. Friston et al., 2003), in conjunction with
635 cognitive tasks targeting the model-based and model-free control systems.

- Adams RA, Huys QJ, Roiser JP (2016) Computational Psychiatry: towards a mathematically informed understanding of mental illness. *J Neurol Neurosurg Psychiatry* 87:53-63.
- Afraimovich V, Tristan I, Huerta R, Rabinovich MI (2008) Winnerless competition principle and prediction of the transient dynamics in a Lotka-Volterra model. *Chaos* 18:043103.
- Amit DJ (1989) Modeling brain function: the world of attractor neural networks. Cambridge ; New York: Cambridge University Press.
- Baldassarre G, Mannella F, Fiore VG, Redgrave P, Gurney K, Mirolli M (2013) Intrinsically motivated action-outcome learning and goal-based action recall: a system-level bio-constrained computational model. *Neural Netw* 41:168-187.
- Balleine BW (2005) Neural bases of food-seeking: affect, arousal and reward in corticostriatolimbic circuits. *Physiol Behav* 86:717-730.
- Balleine BW, O'Doherty JP (2010) Human and rodent homologies in action control: corticostriatal determinants of goal-directed and habitual action. *Neuropsychopharmacology* 35:48-69.
- Belcher AM, Volkow ND, Moeller FG, Ferre S (2014) Personality traits and vulnerability or resilience to substance use disorders. *Trends Cogn Sci* 18:211-217.
- Belin D, Everitt BJ (2008) Cocaine seeking habits depend upon dopamine-dependent serial connectivity linking the ventral with the dorsal striatum. *Neuron* 57:432-441.
- Belin D, Deroche-Gamonet V (2012) Responses to novelty and vulnerability to cocaine addiction: contribution of a multi-symptomatic animal model. *Cold Spring Harbor perspectives in medicine* 2.
- Belin D, Belin-Rauscent A, Everitt BJ, Dalley JW (2016) In search of predictive endophenotypes in addiction: insights from preclinical research. *Genes, brain, and behavior* 15:74-88.
- Belin D, Mar AC, Dalley JW, Robbins TW, Everitt BJ (2008) High impulsivity predicts the switch to compulsive cocaine-taking. *Science* 320:1352-1355.
- Belin D, Berson N, Balado E, Piazza PV, Deroche-Gamonet V (2011) High-novelty-preference rats are predisposed to compulsive cocaine self-administration. *Neuropsychopharmacology* 36:569-579.
- Bellman R (1966) Dynamic programming. *Science* 153:34-37.
- Carroll ME, Morgan AD, Lynch WJ, Campbell UC, Dess NK (2002) Intravenous cocaine and heroin self-administration in rats selectively bred for differential saccharin intake: phenotype and sex differences. *Psychopharmacology (Berl)* 161:304-313.
- Cohen MX, Frank MJ (2009) Neurocomputational models of basal ganglia function in learning, memory and choice. *Behavioural brain research* 199:141-156.
- Covington HE, 3rd, Miczek KA (2005) Intense cocaine self-administration after episodic social defeat stress, but not after aggressive behavior: dissociation from corticosterone activation. *Psychopharmacology (Berl)* 183:331-340.
- Dalley JW, Everitt BJ, Robbins TW (2011) Impulsivity, compulsivity, and top-down cognitive control. *Neuron* 69:680-694.
- Dalley JW, Fryer TD, Brichard L, Robinson ES, Theobald DE, Laane K, Pena Y, Murphy ER, Shah Y, Probst K, Abakumova I, Aigbirhio FI, Richards HK, Hong Y, Baron JC, Everitt

- 680 BJ, Robbins TW (2007) Nucleus accumbens D2/3 receptors predict trait impulsivity
681 and cocaine reinforcement. *Science* 315:1267-1270.
- 682 Daw ND, Dayan P (2014) The algorithmic anatomy of model-based evaluation. *Philos Trans*
683 *R Soc Lond B Biol Sci* 369.
- 684 Daw ND, Niv Y, Dayan P (2005) Uncertainty-based competition between prefrontal and
685 dorsolateral striatal systems for behavioral control. *Nat Neurosci* 8:1704-1711.
- 686 Daw ND, Gershman SJ, Seymour B, Dayan P, Dolan RJ (2011) Model-based influences on
687 humans' choices and striatal prediction errors. *Neuron* 69:1204-1215.
- 688 Dayan P (2009) Dopamine, reinforcement learning, and addiction. *Pharmacopsychiatry* 42
689 Suppl 1:S56-65.
- 690 Deco G, Jirsa VK, Robinson PA, Breakspear M, Friston K (2008) The dynamic brain: from
691 spiking neurons to neural masses and cortical fields. *PLoS Comput Biol* 4:e1000092.
- 692 desJardins ME, Durfee EH, Ortiz J, Charles L., Wolverton MJ (1999) A survey of research in
693 distributed, continual planning. *AI Magazine* 20:13-22.
- 694 Dilleen R, Pelloux Y, Mar AC, Molander A, Robbins TW, Everitt BJ, Dalley JW, Belin D (2012)
695 High anxiety is a predisposing endophenotype for loss of control over cocaine, but
696 not heroin, self-administration in rats. *Psychopharmacology (Berl)* 222:89-97.
- 697 Dolan RJ, Dayan P (2013) Goals and habits in the brain. *Neuron* 80:312-325.
- 698 Doll BB, Daw ND (2016) The expanding role of dopamine. *Elife* 5.
- 699 Doll BB, Jacobs WJ, Sanfey AG, Frank MJ (2009) Instructional control of reinforcement
700 learning: a behavioral and neurocomputational investigation. *Brain Res* 1299:74-94.
- 701 Draganski B, Kherif F, Kloppel S, Cook PA, Alexander DC, Parker GJ, Deichmann R,
702 Ashburner J, Frackowiak RS (2008) Evidence for segregated and integrative
703 connectivity patterns in the human Basal Ganglia. *J Neurosci* 28:7143-7152.
- 704 Economidou D, Pelloux Y, Robbins TW, Dalley JW, Everitt BJ (2009) High impulsivity
705 predicts relapse to cocaine-seeking after punishment-induced abstinence. *Biol*
706 *Psychiatry* 65:851-856.
- 707 Ersche KD, Turton AJ, Pradhan S, Bullmore ET, Robbins TW (2010) Drug addiction
708 endophenotypes: impulsive versus sensation-seeking personality traits. *Biol*
709 *Psychiatry* 68:770-773.
- 710 Everitt BJ, Robbins TW (2013) From the ventral to the dorsal striatum: devolving views of
711 their roles in drug addiction. *Neurosci Biobehav Rev* 37:1946-1954.
- 712 Everitt BJ, Robbins TW (2016) Drug Addiction: Updating Actions to Habits to Compulsions
713 Ten Years On. *Annu Rev Psychol* 67:23-50.
- 714 Fiore VG, Dolan RJ, Strausfeld NJ, Hirth F (2015) Evolutionarily conserved mechanisms for
715 the selection and maintenance of behavioural activity. *Philos Trans R Soc Lond B*
716 *Biol Sci* 370.
- 717 Fiore VG, Nolte T, Rigoli F, Smittenaar P, Gu X, Dolan RJ (2018) Value encoding in the globus
718 pallidus: fMRI reveals an interaction effect between reward and dopamine drive.
719 *Neuroimage* 173:249-257.
- 720 Fiore VG, Rigoli F, Stenner MP, Zaehle T, Hirth F, Heinze HJ, Dolan RJ (2016) Changing
721 pattern in the basal ganglia: motor switching under reduced dopaminergic drive. *Sci*
722 *Rep* 6:23327.
- 723 Fiore VG, Sperati V, Mannella F, Mirolli M, Gurney K, Friston K, Dolan RJ, Baldassarre G
724 (2014) Keep focussing: striatal dopamine multiple functions resolved in a single
725 mechanism tested in a simulated humanoid robot. *Front Psychol* 5:124.

- 726 Flagel SB, Waselus M, Clinton SM, Watson SJ, Akil H (2014) Antecedents and consequences
727 of drug abuse in rats selectively bred for high and low response to novelty.
728 *Neuropharmacology* 76 Pt B:425-436.
- 729 Flagel SB, Robinson TE, Clark JJ, Clinton SM, Watson SJ, Seeman P, Phillips PE, Akil H (2010)
730 An animal model of genetic vulnerability to behavioral disinhibition and
731 responsiveness to reward-related cues: implications for addiction.
732 *Neuropsychopharmacology* 35:388-400.
- 733 Friston KJ, Harrison L, Penny W (2003) Dynamic causal modelling. *Neuroimage* 19:1273-
734 1302.
- 735 Gannon BM, Galindo KI, Rice KC, Collins GT (2017) Individual Differences in the Relative
736 Reinforcing Effects of 3,4-Methylenedioxypyrovalerone under Fixed and
737 Progressive Ratio Schedules of Reinforcement in Rats. *The Journal of pharmacology*
738 *and experimental therapeutics* 361:181-189.
- 739 Garrison KA, Potenza MN (2014) Neuroimaging and biomarkers in addiction treatment.
740 *Current psychiatry reports* 16:513.
- 741 Gerfen CR, Surmeier DJ (2011) Modulation of striatal projection systems by dopamine.
742 *Annu Rev Neurosci* 34:441-466.
- 743 Gershman SJ, Horvitz EJ, Tenenbaum JB (2015) Computational rationality: A converging
744 paradigm for intelligence in brains, minds, and machines. *Science* 349:273-278.
- 745 Gillan CM, Kosinski M, Whelan R, Phelps EA, Daw ND (2016) Characterizing a psychiatric
746 symptom dimension related to deficits in goal-directed control. *Elife* 5.
- 747 Gould RW, Duke AN, Nader MA (2014) PET studies in nonhuman primate models of cocaine
748 abuse: translational research related to vulnerability and neuroadaptations.
749 *Neuropharmacology* 84:138-151.
- 750 Grahn JA, Parkinson JA, Owen AM (2009) The role of the basal ganglia in learning and
751 memory: neuropsychological studies. *Behavioural brain research* 199:53-60.
- 752 Gruber AJ, McDonald RJ (2012) Context, emotion, and the strategic pursuit of goals:
753 interactions among multiple brain systems controlling motivated behavior. *Front*
754 *Behav Neurosci* 6:50.
- 755 Gutkin BS, Dehaene S, Changeux JP (2006) A neurocomputational hypothesis for nicotine
756 addiction. *Proc Natl Acad Sci U S A* 103:1106-1111.
- 757 Haber S (2008) Parallel and integrative processing through the Basal Ganglia reward
758 circuit: lessons from addiction. *Biol Psychiatry* 64:173-174.
- 759 Haber SN (2003) The primate basal ganglia: parallel and integrative networks. *J Chem*
760 *Neuroanat* 26:317-330.
- 761 Hauser TU, Fiore VG, Moutoussis M, Dolan RJ (2016) Computational Psychiatry of ADHD:
762 Neural Gain Impairments across Marrian Levels of Analysis. *Trends Neurosci* 39:63-
763 73.
- 764 Hoffman RE, McGlashan TH (2001) Neural network models of schizophrenia.
765 *Neuroscientist* 7:441-454.
- 766 Huys QJ, Maia TV, Frank MJ (2016) Computational psychiatry as a bridge from
767 neuroscience to clinical applications. *Nat Neurosci* 19:404-413.
- 768 Hyman SE, Malenka RC, Nestler EJ (2006) Neural mechanisms of addiction: the role of
769 reward-related learning and memory. *Annu Rev Neurosci* 29:565-598.
- 770 Jahanshahi M, Obeso I, Rothwell JC, Obeso JA (2015) A fronto-striato-subthalamic-pallidal
771 network for goal-directed and habitual inhibition. *Nat Rev Neurosci* 16:719-732.

- 772 Jimenez VA, Grant KA (2017) Studies using macaque monkeys to address excessive alcohol
773 drinking and stress interactions. *Neuropharmacology* 122:127-135.
- 774 Jonkman S, Pelloux Y, Everitt BJ (2012) Drug intake is sufficient, but conditioning is not
775 necessary for the emergence of compulsive cocaine seeking after extended self-
776 administration. *Neuropsychopharmacology* 37:1612-1619.
- 777 Jupp B, Dalley JW (2014) Behavioral endophenotypes of drug addiction: Etiological insights
778 from neuroimaging studies. *Neuropharmacology* 76 Pt B:487-497.
- 779 Keramati M, Dezfouli A, Piray P (2011) Speed/accuracy trade-off between the habitual and
780 the goal-directed processes. *PLoS Comput Biol* 7:e1002055.
- 781 Koob GF, Volkow ND (2016) Neurobiology of addiction: a neurocircuitry analysis. *The*
782 *lancet Psychiatry* 3:760-773.
- 783 Maia TV, Frank MJ (2011) From reinforcement learning models to psychiatric and
784 neurological disorders. *Nat Neurosci* 14:154-162.
- 785 Marr D, Poggio T (1976) From understanding computation to understanding neural
786 circuitry. Cambridge: Massachusetts Institute of Technology, Artificial Intelligence
787 Laboratory.
- 788 McClintick MN, Grant KA (2016) Aggressive temperament predicts ethanol self-
789 administration in late adolescent male and female rhesus macaques.
790 *Psychopharmacology (Berl)* 233:3965-3976.
- 791 Molander AC, Mar A, Norbury A, Steventon S, Moreno M, Caprioli D, Theobald DE, Belin D,
792 Everitt BJ, Robbins TW, Dalley JW (2011) High impulsivity predicting vulnerability
793 to cocaine addiction in rats: some relationship with novelty preference but not
794 novelty reactivity, anxiety or stress. *Psychopharmacology (Berl)* 215:721-731.
- 795 Montague PR, Dolan RJ, Friston KJ, Dayan P (2012) Computational psychiatry. *Trends Cogn*
796 *Sci* 16:72-80.
- 797 Moore A, Atkeson CG (1993) Prioritized sweeping: Reinforcement learning with less data
798 and less time. *Machine Learning* 13:103-130.
- 799 Morgan D, Grant KA, Gage HD, Mach RH, Kaplan JR, Prioleau O, Nader SH, Buchheimer N,
800 Ehrenkaufer RL, Nader MA (2002) Social dominance in monkeys: dopamine D2
801 receptors and cocaine self-administration. *Nat Neurosci* 5:169-174.
- 802 Nadal R, Armario A, Janak PH (2002) Positive relationship between activity in a novel
803 environment and operant ethanol self-administration in rats. *Psychopharmacology*
804 *(Berl)* 162:333-338.
- 805 Nader MA, Czoty PW (2005) PET imaging of dopamine D2 receptors in monkey models of
806 cocaine abuse: genetic predisposition versus environmental modulation. *Am J*
807 *Psychiatry* 162:1473-1482.
- 808 Nestler EJ, Aghajanian GK (1997) Molecular and cellular basis of addiction. *Science* 278:58-
809 63.
- 810 Obeso JA, Rodriguez-Oroz MC, Stamelou M, Bhatia KP, Burn DJ (2014) The expanding
811 universe of disorders of the basal ganglia. *Lancet* 384:523-531.
- 812 Pelloux Y, Everitt BJ, Dickinson A (2007) Compulsive drug seeking by rats under
813 punishment: effects of drug taking history. *Psychopharmacology (Berl)* 194:127-
814 137.
- 815 Pelloux Y, Murray JE, Everitt BJ (2015) Differential vulnerability to the punishment of
816 cocaine related behaviours: effects of locus of punishment, cocaine taking history
817 and alternative reinforcer availability. *Psychopharmacology (Berl)* 232:125-134.

- 818 Perry JL, Carroll ME (2008) The role of impulsive behavior in drug abuse.
819 Psychopharmacology (Berl) 200:1-26.
- 820 Pezzulo G, Rigoli F, Chersi F (2013) The mixed instrumental controller: using value of
821 information to combine habitual choice and mental simulation. Front Psychol 4:92.
- 822 Piazza PV, Deminiere JM, Le Moal M, Simon H (1989) Factors that predict individual
823 vulnerability to amphetamine self-administration. Science 245:1511-1513.
- 824 Piray P, Keramati MM, Dezfouli A, Lucas C, Mokri A (2010) Individual differences in nucleus
825 accumbens dopamine receptors predict development of addiction-like behavior: a
826 computational approach. Neural Comput 22:2334-2368.
- 827 Rabinovich MI, Varona P, Selverston AI, Abarbanel HDI (2006) Dynamical principles in
828 neuroscience. Reviews of Modern Physics 78.
- 829 Redish AD (2004) Addiction as a computational process gone awry. Science 306:1944-
830 1947.
- 831 Redish AD, Jensen S, Johnson A (2008) A unified framework for addiction: vulnerabilities in
832 the decision process. Behav Brain Sci 31:415-437; discussion 437-487.
- 833 Sadacca BF, Jones JL, Schoenbaum G (2016) Midbrain dopamine neurons compute inferred
834 and cached value prediction errors in a common framework. Elife 5.
- 835 Schultz W, Dayan P, Montague PR (1997) A neural substrate of prediction and reward.
836 Science 275:1593-1599.
- 837 Silver D, Huang A, Maddison CJ, Guez A, Sifre L, van den Driessche G, Schrittwieser J,
838 Antonoglou I, Panneershelvam V, Lanctot M, Dieleman S, Grewe D, Nham J,
839 Kalchbrenner N, Sutskever I, Lillicrap T, Leach M, Kavukcuoglu K, Graepel T,
840 Hassabis D (2016) Mastering the game of Go with deep neural networks and tree
841 search. Nature 529:484-489.
- 842 Simon DA, Daw ND (2012) Dual-system learning models and drugs of abuse. In:
843 Computational Neuroscience of Drug Addiction, 1 Edition (Gutkin B, Ahmed SH,
844 eds), pp 145–161. New York: Springer-Verlag.
- 845 Singh S, Jaakkola T, Littman ML, Szepesvári C (2000) Convergence Results for Single-Step
846 On-Policy Reinforcement-Learning Algorithms. Machine Learning 38:287-308.
- 847 Smethells JR, Zlebnik NE, Miller DK, Will MJ, Booth F, Carroll ME (2016) Cocaine self-
848 administration and reinstatement in female rats selectively bred for high and low
849 voluntary running. Drug and alcohol dependence 167:163-168.
- 850 Suto N, Austin JD, Vezina P (2001) Locomotor response to novelty predicts a rat's
851 propensity to self-administer nicotine. Psychopharmacology (Berl) 158:175-180.
- 852 Sutton RS (1990) Integrated architecture for learning, planning, and reacting based on
853 approximating dynamic programming. In: Proceedings of the seventh international
854 conference (1990) on Machine learning, pp 216-224. Austin, Texas, USA: Morgan
855 Kaufmann Publishers Inc.
- 856 Sutton RS, Barto AG (1998) Reinforcement Learning: An Introduction. Cambridge, MA: MIT
857 Press.
- 858 Verdejo-Garcia A, Lawrence AJ, Clark L (2008) Impulsivity as a vulnerability marker for
859 substance-use disorders: review of findings from high-risk research, problem
860 gamblers and genetic association studies. Neurosci Biobehav Rev 32:777-810.
- 861 Volkow ND, Morales M (2015) The Brain on Drugs: From Reward to Addiction. Cell
862 162:712-725.

- 863 Volkow ND, Fowler JS, Wang GJ, Swanson JM, Telang F (2007) Dopamine in drug abuse and
864 addiction: results of imaging studies and treatment implications. *Archives of*
865 *neurology* 64:1575-1579.
- 866 Voon V, Reiter A, Sebold M, Groman S (2017) Model-Based Control in Dimensional
867 *Psychiatry*. *Biol Psychiatry* 82:391-400.
- 868 Watkins CJ, Dayan P (1992) Q-Learning. *Machine Learning* 8:279-292.
- 869 Willuhn I, Burgeno LM, Everitt BJ, Phillips PE (2012) Hierarchical recruitment of phasic
870 dopamine signaling in the striatum during the progression of cocaine use. *Proc Natl*
871 *Acad Sci U S A* 109:20703-20708.
- 872 Yin HH, Knowlton BJ, Balleine BW (2004) Lesions of dorsolateral striatum preserve
873 outcome expectancy but disrupt habit formation in instrumental learning. *Eur J*
874 *Neurosci* 19:181-189.
- 875

876 **Extended Data Code File 1.** To access the source code of both models, visit the ModelDB
877 website (<https://senselab.med.yale.edu/modeldb/enterCode.cshhtml?model=239540>), and
878 download the archive. The source code shows its structure in the commented main files
879 “separate_test.m” and “RunExperimentLearning96.m”, respectively in the folder “neural_model”
880 and “RL_model”.

881
882
883 **Figure 1. Illustrative representation of energy landscapes and neural architecture of the**
884 **model. A-C.** These representations of energy landscapes are meant to illustrate differences in the
885 temporal responses provided by neural systems. Depending on the energy landscape, three
886 arbitrary inputs (magenta dots) are transformed into different stable states (grey dots). Learning
887 processes increase or decrease the strength of the connections among nodes in a network, thereby
888 altering its energy landscape and reshaping temporal responses towards existing attractors.
889 Attractors are defined as low energy states (bottom of the basins) at the end point of the temporal
890 responses to multiple starting inputs. **(A)** The landscape is characterized by multiple shallow
891 attractors: these allow slow temporal responses, transforming multiple inputs into multiple
892 weakly stable states. Noise and changes in the incoming input easily determine new responses
893 towards different attractors. **(B)** In this second illustrative configuration, steep and vast attractors
894 characterize the energy landscape, allowing quick state transitions towards two equilibrium
895 points. This new configuration is able to resist noise and minor changes in the incoming input,
896 and, at the same time, allows a differentiation of inputs in two broad categories. **(C)** Finally, the
897 third energy landscape illustrates the presence of a parasitic attractor, exemplifying the condition
898 of addiction: all inputs fall now at the bottom of a single steep basin. Under this condition, noise

899 and changes in the incoming input determine temporal responses that keep falling in the same
 900 attractor, therefore preventing the system from executing different behaviors. **(D)** Neural
 901 architecture used to simulate neural dynamics and behavior for the mean field neural model. The
 902 activity in the dorsal cortico-striatal circuit is responsible for the motor output of the system (left
 903 circuit), whilst activity in the ventral cortico-striatal circuit is responsible for goal selections
 904 (right circuit). The two systems bias each other via cortico-cortical connectivity and learning
 905 processes affect the weights of the connections between the two cortical outputs and the striatum
 906 in their corresponding circuits. The components in the architecture are labeled as follows: cortex
 907 (Cx), thalamus (Th), globus pallidus pars externa and interna (GPe and GPi), substantia nigra
 908 pars reticulata (SNr), sub-thalamic nucleus (STN) and striatum (Str), divided into two areas
 909 enriched by either D1 or D2 receptors.

910

911 **Figure 2. Illustrative representation of the environment used for the RL model of**
 912 **addiction.** The states are disposed in a linear arrangement: on one extreme is a healthy reward
 913 state (1), on the opposite side a drug state (8) followed by twelve aftereffects states (9-22).
 914 Healthy reward and drug states are separated by 6 neutral states (2-7). The agent can traverse
 915 between nearby neutral states. From the two borders of the central segment of neutral states, an
 916 agent can enter the healthy reward state (from state 2), securing a moderate reward ($R_g=1$), or
 917 the drug state (from state 7), receiving an initial high reward ($R_d=10$, during the phase of
 918 addiction) and a series of sparse but temporally extended negative outcomes, characterizing the
 919 aftereffects states. The presence of negative outcomes makes entering the drug and aftereffects
 920 area suboptimal during all experimental phases (see optimal policy in **table 3**). From both the
 921 goal state and the drug/aftereffects segment the agent is then returned to the middle of the neutral

segment. In this representation, we explicitly portray the transitions related to states 1 (healthy reward), 4 (neutral), and 15 and 20 (drug aftereffects) for illustrative purposes. Line width represents related transition probability value. Line and text color represent the action class (a_s , a_g , a_w , a_d). Neutral states are navigable with actions a_{s2-7} which are deterministic for adjacent state while have high chance of failing for distant states. From the neutral states the agent can reach: (i) the healthy reward, if executing action a_g when in state 2; and (ii) the drug state (8) and aftereffects area (state 9 to 22), if executing action a_d , when in state 7. From the healthy reward area the agent can issue again a_g , receiving a reward of 1 and going back to the center of the neutral area, state 4. By entering the drug area, the agent receives a reward of 10. Action results in the drug/aftereffect area are probabilistic: the agent can reach a nearby state in the area or leave the area and reach the center of the neutral state. Leaving the drug/aftereffects area has a cost of -4, whereas every other transition inside the area costs -1.2. For a full description of transitions and their probability distribution in the environment (see **Tables 1-2,4-5**).

Figure 3. Distribution of action selections across endophenotypes controlled by the neural model. Histograms show how the distribution of simulated action selections changes depending on the endophenotype (11 variations in cortico-cortical connectivity weights). 30 random seeds/inputs are used per endophenotype, tested under two stages: pre-drug (**A**) and addiction (**B**). The three colors represent the occurrence of selections of three arbitrary actions. Under the pre-drug stage, no reward is provided and action selections are triggered by random fluctuation in values of competing sensory inputs. The simulations show the agents adapt to the changes in sensory stimuli and therefore exhibit a near-uniform distribution of action selections. Conversely, under the addiction stage, the action represented in blue is associated with

administration of the simulated drug, triggering DA-dependent Hebbian learning in cortico-striatal connectivity, and consequently over-selection. Under addiction, the differences among endophenotypes clearly emerge in the selection frequency of the action leading to drug consumption. Asymmetric control (endophenotypes 1-3 and 9-11) leads to a stronger over-selection in comparison with balanced control (endophenotypes 4-7), despite identical learning processes and reward encoding.

951

Figure 4. Severity of addiction and relapse time across endophenotypes controlled by the neural model. Shaded error bars report mean and standard error for 30 simulated agents across endophenotypes (11 variations in cortico-cortical connectivity weights). Panels A and B show the selections of actions leading to substance consumption, as a percentage of the overall number of action selections. In the first case (**A**) we compare the values recorded during the addiction stage with those recorded during the stage of dorsal treatment jointly with abstinence (i.e. drug-related actions do not trigger self-administration of a drug and the treatment targets the dorsal circuit). In the second case (**B**) the comparison involves addiction and ventral treatment (treatment targeting the ventral circuit, during abstinence). Panels C and D compare the simulated time required by the 11 endophenotypes to reach an arbitrary threshold of cortico-striatal connectivity during the stage of addiction and during the stage of relapse after either dorsal (**C**) or ventral (**D**) treatment. Within the time of a simulation run, all simulated agents reached the addiction threshold. The two treatments are simulated by restoring either the dorsal/motor (A-C) or the ventral/outcome circuit (B-D) to the configuration characterizing the pre-drug stage. The percentage of the action selections shows the dorsal treatment is more effective in endophenotypes characterized by high dorsal dominance (**A**), whereas the ventral

968 treatment only has an effect in endophenotypes characterized by high ventral dominance (**B**).
969 Similarly, dorsal and ventral treatments result in long relapse times in endophenotypes
970 characterized by high dorsal and high ventral dominance, respectively. (*) indicates significant
971 difference: $p < 0.05$.

972

973 **Figure 5. Likelihood to develop addiction and relapse time across endophenotypes**

974 **controlled by the RL model.** Shaded error bars report mean and standard error for 100

975 simulated agents across 6 endophenotypes (differential balance between model-based and model-

976 free control modalities, $\beta = [0, 0.2, 0.4, 0.6, 0.8, 1]$). Panels A and B show the percentage of

977 agents developing addiction (i.e. drug-related choices are more frequent than healthy reward-

978 related choices), per endophenotype, under the addiction and treatment phases. In the first case

979 (**A**) the comparison involves data recorded during the phase of addiction and those recorded

980 during the phase of model-free treatment. In the second case (**B**) the comparison involves the

981 phases of addiction and model-based treatment. Panels C and D illustrate the simulated time

982 required by the 6 endophenotypes to reach 95% of action preference towards the drug state, in

983 comparison with action preference recorded during the phase of addiction (f2). In the first case

984 (**C**) the comparison involves the phases of addiction and relapse after model-free treatment,

985 whereas in the second case (**D**) the comparison involves the phases of addiction and relapse after

986 model-based treatment. In terms of action selection ratio, the simulated results show both

987 treatments have a significant effect only on those phenotypes characterized by strong unbalance

988 of control (**A-B**). In terms of relapse, the results show the model-free treatment is on average

989 more successful than the model-based one, as 5 endophenotypes show no significant difference

990 between the phases of addiction and post-treatment addiction (i.e. the time required to relapse is

not significantly different than the time required to develop addiction the first time). Each endophenotype, or parameter selection, was simulated 100 times across the four phases (3050 steps per simulation). Results depend on the statics of the environment, but over similar environments the results were qualitatively similar. (*) indicates significant difference: $p < 0.05$.

Table 1 Environment transition probabilities across endophenotypes controlled by the RL model. Changes during phases in italic.

Transition Description	Probability for each phase				
	P (f1)	P (f2)	P (f3)	P (f4)	
$P(s=i s=i, a=a^{s=i})$, i neutral state	1	1	1	1	From Neutral States
$P(s=i+j s=i, a=a^{s=i+j})$, $j=+1/-1$, i neutral state, i+j neutral state	0.99	0.99	0.99	0.99	
$P(s=i s=i, a=a^{s=i+j})$, $j=+1/-1$, i neutral state, i+j neutral state	0.01	0.01	0.01	0.01	
$P(s=i+k s=i, a=a^{s=i+k})$, $k!=+1/-1$, i neutral state, i+k neutral state	0.0001	0.0001	0.0001	0.0001	
$P(s=i s=i, a=a^{s=i+k})$, $k!=+1/-1$, i neutral state, i+k neutral state	0.9999	0.9999	0.9999	0.9999	
$P(s=i s=i, a=a^w)$, i neutral state	1	1	1	1	
$P(s=1 s=2, a=a^g)$	1	1	1	1	
$P(s=i s=i, a=a^g)$, $i!=2$ neutral state	1	1	1	1	
$P(s=8 s=7, a=a^d)$	1	1	1	1	

$P(s=i s=i, a=a^d), i!=7$ neutral state	1	1	1	1	
$P(s=i s=i, a=a^g), i$ drug/aft state	0.999	0.999	<i>0.8</i>	0.999	From Drug/aft States
$P(s=4 s=i, a=a^g), i$ drug/aft state	0.001	0.001	<i>0.2</i>	0.001	
$P(s=i s=i, a=a^{s=*}), i$ drug/aft state	0.999	0.999	<i>0.8</i>	0.999	
$P(s=4 s=i, a=a^{s=*}), i$ drug/aft state	0.001	0.001	<i>0.2</i>	0.001	
$P(s=j s=i, a=a^w), i!=15$ drug/aft state, j next or previous drug/aft state	0.4995	0.4995	<i>0.4</i>	4.995	
$P(s=4 s=i, a=a^w), i!=15$ drug/aft state	0.001	0.001	<i>0.2</i>	0.001	
$P(s=14/16 s=15, a=a^w)$	0.2	0.2	<i>0.15</i>	0.2	
$P(s=4 s=15, a=a^w)$	0.6	0.6	<i>0.7</i>	0.6	
$P(s=j s=i, a=a^d), i$ drug/aft state, j next drug/aft state	0.745	0.745	<i>0.6</i>	0.745	
$P(s=j s=i, a=a^d), i$ drug/aft state, j previous drug/aft state	0.245	0.245	<i>0.2</i>	0.245	
$P(s=4 s=i, a=a^d), i$ drug/aft state	0.01	0.01	<i>0.2</i>	0.01	
$P(s=4 s=1, a=a^g)$	1	1	1	1	Goal
$P(s=1 s=1, a=a^{s=*})$	1	1	1	1	
$P(s=1 s=1, a=a^w)$	1	1	1	1	
$P(s=1 s=1, a=a^d)$	1	1	1	1	

999

1000 **Table 2** Environment rewards across endophenotypes controlled by the RL model. Changes
 1001 during phases in italic.

Transition Description	Probability for each phase	
------------------------	----------------------------	--

	P (f1)	P (f2)	P (f3)	P (f4)	
$T(s=i s=i, a=a^{s=i}), i \text{ neutral state}$	0	0	0	0	From States
$T(s=i+j s=i, a=a^{s=i+j}), j=+1/-1, i \text{ neutral state, } i+j \text{ neutral state}$	0	0	0	0	
$T(s=i s=i, a=a^{s=i+j}), j=+1/-1, i \text{ neutral state, } i+j \text{ neutral state}$	0	0	0	0	
$T(s=i+k s=i, a=a^{s=i+k}), k!=+1/-1, i \text{ neutral state, } i+k \text{ neutral state}$	-0.3	-0.3	-0.3	-0.3	
$T(s=i s=i, a=a^{s=i+k}), k!=+1/-1, i \text{ neutral state, } i+k \text{ neutral state}$	0	0	0	0	
$T(s=i s=i, a=a^w), i \text{ neutral state}$	0	0	0	0	
$T(s=1 s=2, a=a^g)$	0	0	0	0	
$T(s=i s=i, a=a^g), i!=2 \text{ neutral state}$	0	0	0	0	
$T(s=8 s=7, a=a^d)$	0	10	-1	10	
$T(s=i s=i, a=a^d), i!=7 \text{ neutral state}$	0	0	0	0	
$T(s=i s=i, a=a^g), i \text{ drug/aft state}$	-0.3	-1.2	-1.2	-1.2	From Drug/aft States
$T(s=4 s=i, a=a^g), i \text{ drug/aft state}$	-4	-4	-4	-4	
$T(s=i s=i, a=a^{s=*}), i \text{ drug/aft state}$	-0.3	-1.2	-1.2	-1.2	
$T(s=4 s=i, a=a^{s=*}), i \text{ drug/aft state}$	-4	-4	-4	-4	
$T(s=j s=i, a=a^w), i!=15 \text{ drug/aft state, } j \text{ next or previous drug/aft state}$	-0.3	-1.2	-1.2	-1.2	
$T(s=4 s=i, a=a^w), i!=15 \text{ drug/aft state}$	-4	-4	-4	-4	
$T(s=14/16 s=15, a=a^w)$	-0.3	-1.2	-1.2	-1.2	

$T(s=4 s=15, a=a^w)$	-4	-4	-4	-4	
$T(s=j s=i, a=a^d)$, i drug/aft state, j next drug/aft state	-0.3	-1.2	-1.2	-1.2	
$T(s=j s=i, a=a^d)$, i drug/aft state, j previous drug/aft state	-0.3	-1.2	-1.2	-1.2	
$T(s=4 s=i, a=a^d)$, i drug/aft state	-4	-4	-4	-4	
$T(s=4 s=1, a=a^g)$	1	1	1	1	Goal
$T(s=1 s=1, a=a^{s^*})$	0	0	0	0	
$T(s=1 s=1, a=a^w)$	0	0	0	0	
$T(s=1 s=1, a=a^d)$	0	0	0	0	

1002

1003 **Table 3** Optimal policy across endophenotypes controlled by the RL model (2nd Drug phase)

State Id	State Type	Action	Q value
1	goal	a^g	2.8967
2	neutral	a^g	2.607
3	neutral	$a^{s=2}$	2.3439
4	neutral	$a^{s=3}$	2.1074
5	neutral	$a^{s=4}$	1.8948
6	neutral	$a^{s=5}$	1.7036
7	neutral	$a^{s=6}$	1.5317
8	drug	a^d	-10.1134
9	drug-aft	a^d	-10.3781
10	drug-aft	a^w	-10.4882

11	drug-aft	a^w	-10.2809
12	drug-aft	a^w	-9.7099
13	drug-aft	a^w	-8.6469
14	drug-aft	a^w	-6.8532
15	drug-aft	a^w	-3.9265
16	drug-aft	a^d	-5.2928
17	drug-aft	a^d	-6.4251
18	drug-aft	a^d	-7.3633
19	drug-aft	a^d	-8.1408
20	drug-aft	a^d	-8.7849
21	drug-aft	a^d	-9.318
22	drug-aft	a^d	-9.7575

1004

1005 **Table 4** Agent model parameters across endophenotypes controlled by the RL model

Name	Description	Value
α	MF learning factor	0.05
γ	Discount factor	0.9
d_{MB}	MB decay factor	0.01
N_{PS}	MB number of updates	50
T_{MB}	Temperature for stochastic state update selection	1
ε	Exploration factor	0.1
α_{Ctpy}	Cognitive therapy MF learning factor	0.0001, 0.0005, 0.001

1006

1007 **Table 5** Environment parameters across endophenotypes controlled by the RL model.

Name	Description	Value
N_T	Number of states	22
N_G	Number Goal States	1
N_D	Number Drug/aft States	15
N_n	Number Neutral States	6
N_a	Number of actions	9
S_0	Starting state	4
R_p	Punishment end of drug/aft consumption	-4
R_c	Punishment in drug/aft area	-1.2
R_{dd}	Reward at init drug consumption (f2,f4)	10
R_{dt}	Reward at init drug consumption in therapy	-1
R_g	Reward when entering goal state	1
d_{init}	Duration initial (no drug) phase	50
d_{drug1}	Duration first drug phase	1000
d_{tpy}	Duration therapy phase	1000
d_{drug2}	Duration second drug phase	600

1008









